Endeavor BioMedicines reposted this
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: John Hood on Endeavor BioMedicines' $132.5M series C and hedgehog inhibition for IPF. He describes the fundraising environment in biotech and the phase 2 data in IPF that Endeavor unveiled in January and enabled this week's raise. Full video: https://lnkd.in/g8mHpV3Y BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
Principal at Biran Capital
2moCongrats! Always nice to hear a good data readout as a leading cause for a successful fundraise. Best wishes 🙏🏼👍🏼🙂